BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The world first became aware of Covid-19 five years ago. We evaluate where we are, remember how we got here, and consider ...

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Biontech SE agreed to pay up to nearly $1.26 billion in two separate settlements to resolve royalty disputes with the U.S. NIH and the University of Pennsylvania related to the COVID-19 vaccine the ...

Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

The German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a royalties dispute with the US Na ...

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...